These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 4751256)

  • 21. Modification of transplantability and tumor growth following treatment of L1210 leukemia and TA3Ha cells with macromomycin (NSC-170105).
    Lippman MM; Abbott BJ
    Cancer Chemother Rep; 1973; 57(4):501-3. PubMed ID: 4762442
    [No Abstract]   [Full Text] [Related]  

  • 22. Effectiveness of antileukemic agents in mice inoculated with leukemia L1210 variants resistant to 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) or 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196).
    Kline I; Woodman RJ; Gang M; Venditti JM
    Cancer Chemother Rep; 1971 Feb; 55(1):9-28. PubMed ID: 5121657
    [No Abstract]   [Full Text] [Related]  

  • 23. Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).
    Woodman RJ
    Cancer Chemother Rep 2; 1974 Mar; 4(1):45-52. PubMed ID: 4826499
    [No Abstract]   [Full Text] [Related]  

  • 24. Antileukemic synergism between cyclophosphamide and an antitumor platinum compound.
    Walker EM; Gale GR
    Res Commun Chem Pathol Pharmacol; 1973 Sep; 6(2):419-25. PubMed ID: 4750093
    [No Abstract]   [Full Text] [Related]  

  • 25. Combined effects of chemotherapy and immunity against leukemia L1210 in DBA-2 mice.
    Mihich E
    Cancer Res; 1969 Apr; 29(4):848-54. PubMed ID: 4887203
    [No Abstract]   [Full Text] [Related]  

  • 26. Gas chromatographic method for the determination of plasma isophosphamide (NSC-109724).
    Allen LM; Creaven PJ
    Cancer Chemother Rep; 1972 Dec; 56(6):721-3. PubMed ID: 4660630
    [No Abstract]   [Full Text] [Related]  

  • 27. Metabolism of iphosphamide (2-(2-chloroethylamino)-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide) and production of a toxic iphosphamide metabolite.
    Hill DL; Laster WR; Kirk MC; el-Dareer S; Struck RF
    Cancer Res; 1973 May; 33(5):1016-22. PubMed ID: 4703116
    [No Abstract]   [Full Text] [Related]  

  • 28. A new antitumor agent, (alphas, 4s, 5r)-alpha-amino-3-chloro-4-hydroxy-4,5-dihydro-5-isoxazoleacetic acid (NSC-176324): preliminary evaluation against L 1210 mouse leukemia in vivo.
    Martin DG; Hanka LJ; Neil GL
    Cancer Chemother Rep; 1974; 58(6):935-7. PubMed ID: 4217217
    [No Abstract]   [Full Text] [Related]  

  • 29. Cain's quinolinium (NSC 176319): protection of murine L1210 leukemia cells and bone marrow progenitor cells against mechlorethamine cytotoxicity and its application to combination chemotherapy.
    Naujokaitis SA
    Res Commun Chem Pathol Pharmacol; 1981 Oct; 34(1):97-104. PubMed ID: 7313308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of antileukemic (L1210) treatment schedule on disposition of (minus)-emetine hydrochloride (NSC 33669) in normal and leukemic mice.
    Auletta AE; Gery AM; Mead JA
    Cancer Res; 1974 Jul; 34(7):1581-5. PubMed ID: 4833911
    [No Abstract]   [Full Text] [Related]  

  • 31. [Pharmacologic studies with trophosphamide (Ixoten), a new oxazaphosphorineoxide].
    Brock N
    Med Monatsschr; 1973 Sep; 27(9):390-4. PubMed ID: 4768197
    [No Abstract]   [Full Text] [Related]  

  • 32. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. X.
    Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
    Cancer Chemother Rep 2; 1972 Nov; 3(1):1-69. PubMed ID: 4660732
    [No Abstract]   [Full Text] [Related]  

  • 33. Mechanistic studies of a novel antitumor drug, alpha-1,3,5-triglycidyl-s-triazinetrione. Antitumor and cytotoxic effects.
    WU FY; Le Pecq JB
    Mol Pharmacol; 1983 Jan; 23(1):182-9. PubMed ID: 6346048
    [No Abstract]   [Full Text] [Related]  

  • 34. Consideration of the subcutaneously implanted B16 melanoma as a screening model for potential anticancer agents.
    Griswold DP
    Cancer Chemother Rep 2; 1972 Nov; 3(1):315-24. PubMed ID: 4660734
    [No Abstract]   [Full Text] [Related]  

  • 35. Bronchogenic carcinoma: new drugs available for study.
    Slavik M; Carter SK
    Cancer Chemother Rep 3; 1973 Mar; 4(2):265-9. PubMed ID: 4125744
    [No Abstract]   [Full Text] [Related]  

  • 36. [Comparative study of cyclophosphamide, ifosfamide and trofosfamide on Walker-256 carcinosarcoma in embryonated chicken eggs].
    Norpoth K; Witting U; Rauen HM
    Arzneimittelforschung; 1974 Jan; 24(1):86-9. PubMed ID: 4406116
    [No Abstract]   [Full Text] [Related]  

  • 37. Increased immunogenicity of murine lymphatic tumors by pyrazole-4-carboxamide, 3(or 5)-amino (NSC-1402; PCA).
    Nicolin A; Vadlamudi S; Goldin A
    Cancer Chemother Rep; 1973 Feb; 57(1):3-10. PubMed ID: 4704101
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacological and preclinical toxicological studies of 1,2-diaminocyclohexane(isocitrato)platinum(II).
    Macquet JP; Cros S; Armand JP
    Cancer Res; 1984 Sep; 44(9):3736-43. PubMed ID: 6540142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of antitumor effect of cyclophosphamide by thaliblastine in Lewis lung carcinoma and L1210 leukemia in mice.
    Stoychkov JN; Miloushev AS
    Biomedicine; 1980 Apr; 33(2):42-4. PubMed ID: 6447522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of 2-chloro-2'-deoxyadenosine alone and in combination with cyclophosphamide or methotrexate on murine leukemia L1210.
    Góra-Tybor J; Robak T; Warzocha K; Grieb P
    Arch Immunol Ther Exp (Warsz); 1994; 42(1):39-42. PubMed ID: 7503633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.